<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294645</url>
  </required_header>
  <id_info>
    <org_study_id>701</org_study_id>
    <nct_id>NCT00294645</nct_id>
  </id_info>
  <brief_title>PREFER (Pacemaker Remote Follow-Up Evaluation and Review)</brief_title>
  <official_title>Pacemaker Remote Follow-up Evaluation and Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare remote pacemaker follow-up to current standard of care
      follow-up. The study will compare the rate of first diagnosis of clinically actionable events
      between patients who utilize the Medtronic Carelink® Network (Remote arm) versus patients who
      are followed via routine office visits augmented by transtelephonic monitoring (TTM)(Control
      arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Clinically Actionable Events (CAE) were identified based on their relation to other
      comorbidities that may increase the risk of a serious cardiac event. The defined events are:

        1. Atrial Tachycardia/Atrial Fibrillation (AT/AF) episodes of greater than 48 hours defined
           as two consecutive days in which the device records at least 18 hours of AT/AF per day

        2. Ventricular pacing that has increased by 30 percent (relative) since the last device
           interrogation

        3. A sensed ventricular response of greater than 100 beats per minute (BPM) during atrial
           tachyarrhythmia for at least 20 percent of the time since the previous device
           interrogation

        4. Runs of non-sustained ventricular tachycardia (NSVT) greater than 5 beats

        5. New onset of AT/AF among patients with no history of AT/AF

        6. Loss of atrial capture

        7. Loss of ventricular capture

        8. Increase in atrial pacing voltage threshold greater than 1 volt (V)

        9. Increase in ventricular pacing voltage threshold greater than 1 volt (V)

       10. &amp; 11. Significant change in atrial or ventricular lead impedance, defined as any of the
           following:

             1. Less than 200 or greater than 2000 ohms (Ω)

             2. Unstable lead impedance deemed to be clinically actionable

             3. Greater than 50 percent change in lead impedance since last interrogation

      12. Elective Replacement Indicator (ERI)/Battery End of Life (EOL) indicators
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Clinically Actionable Events (CAE) at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Clinically Actionable Events (CAE) are 12 events that were identified based on their relation to other comorbidities that may increase the risk of a serious cardiac event. The CAEs consist of several arrhythmias and device performance parameters such as: Atrial Tachycardia/Atrial Fibrillation (AT/AF) and loss of capture.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Actions Taken in Response to the Diagnosis of Clinically Actionable Events</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Actions categories include: Referral, Office Visit, Medication (Med) Change, Hospitalization, Emergency Room (ER) Visit, Device Reprogrammed, System Modification, Increase Monitoring, Other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of New Onset Atrial Tachycardia/Atrial Fibrillation (AT/AF) at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Remote and Control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Sensed Ventricular Rate Greater Than 100 Beats Per Minute (BPM) During Atrial Tachycardia/Atrial Fibrillation at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Atrial Tachycardia/Atrial Fibrillation Greater Than 48 Hours at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Ventricular Pacing Increase Greater Than 30 Percent at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Non-sustained Ventricular Tachycardia at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Loss of Atrial Capture at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Loss of Ventricular Capture at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Remote and Control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase in Atrial Pacing Voltage Threshold Greater Than 1 Volt (V) at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Remote and Control arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Increase in Ventricular Pacing Voltage Threshold Greater Than 1 Volt (V) at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Change in Atrial Lead Impedance at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Change in Ventricular Lead Impedance at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Diagnosis of Elective Replacement Indicator/Battery End of Life (ERI/EOL) at 12 Months</measure>
    <time_frame>One year post-enrollment</time_frame>
    <description>Compare time to first diagnosis in Control and Remote arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">980</enrollment>
  <condition>Bradycardia</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transtelephonic monitoring at 2 month intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remote</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transtelephonic monitoring (TTM)</intervention_name>
    <description>TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medtronic CareLink® Network</intervention_name>
    <description>Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.</description>
    <arm_group_label>Remote</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been previously implanted with a dual-chamber or single-chamber EnPulse®,
             Kappa 900®, or Adapta® device

          -  Patient agrees to complete all required follow-up transmissions and in-office visits

          -  Patient is capable of operating the TTM monitor and Medtronic CareLink monitor

        Exclusion Criteria:

          -  Patient is an immediate candidate for an implantable cardioverter defibrillator (ICD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PREFER Study Team</last_name>
    <role>Study Chair</role>
    <affiliation>Medtronic</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocean</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towaco</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chen J, Wilkoff BL, Choucair W, Cohen TJ, Crossley GH, Johnson WB, Mongeon LR, Serwer GA, Sherfesee L. Design of the Pacemaker REmote Follow-up Evaluation and Review (PREFER) trial to assess the clinical value of the remote pacemaker interrogation in the management of pacemaker patients. Trials. 2008 Apr 3;9:18. doi: 10.1186/1745-6215-9-18.</citation>
    <PMID>18387185</PMID>
  </reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <results_first_submitted>April 1, 2009</results_first_submitted>
  <results_first_submitted_qc>October 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2010</results_first_posted>
  <last_update_submitted>October 1, 2010</last_update_submitted>
  <last_update_submitted_qc>October 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medtronic</name_title>
    <organization>Cardiac Rhythm Disease Management Clinical Research</organization>
  </responsible_party>
  <keyword>Remote Follow Up</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Bradycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from May 24, 2004 through March 30, 2007 at cardiology and electrophysiology clinics in the United States.</recruitment_details>
      <pre_assignment_details>Of the 980 patients enrolled, 83 were excluded from analysis: incomplete informed consent forms (n=8), devices incompatible with the Medtronic CareLink® Network (n=7), from research centers that closed prior to cleaning data to the extent necessary for inclusion in cohort (n=67), and exited prior to Baseline assessment (n=1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care With TTM</title>
          <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
        </group>
        <group group_id="P2">
          <title>Remote Pacemaker Interrogation</title>
          <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="602"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="510"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care With TTM</title>
          <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
        </group>
        <group group_id="B2">
          <title>Remote Pacemaker Interrogation</title>
          <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="602"/>
            <count group_id="B3" value="897"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="243.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="417"/>
                    <measurement group_id="B3" value="629.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="16.9"/>
                    <measurement group_id="B2" value="68" spread="16.7"/>
                    <measurement group_id="B3" value="68" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="443.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="454.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="602"/>
                    <measurement group_id="B3" value="897.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With First Diagnosis of Clinically Actionable Events (CAE) at 12 Months</title>
        <description>Clinically Actionable Events (CAE) are 12 events that were identified based on their relation to other comorbidities that may increase the risk of a serious cardiac event. The CAEs consist of several arrhythmias and device performance parameters such as: Atrial Tachycardia/Atrial Fibrillation (AT/AF) and loss of capture.</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Clinically Actionable Events (CAE) at 12 Months</title>
          <description>Clinically Actionable Events (CAE) are 12 events that were identified based on their relation to other comorbidities that may increase the risk of a serious cardiac event. The CAEs consist of several arrhythmias and device performance parameters such as: Atrial Tachycardia/Atrial Fibrillation (AT/AF) and loss of capture.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: control rate = remote rate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Modified Peto-Peto</method>
            <method_desc>A one-sided test was used.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Actions Taken in Response to the Diagnosis of Clinically Actionable Events</title>
        <description>Actions categories include: Referral, Office Visit, Medication (Med) Change, Hospitalization, Emergency Room (ER) Visit, Device Reprogrammed, System Modification, Increase Monitoring, Other</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Actions Taken in Response to the Diagnosis of Clinically Actionable Events</title>
          <description>Actions categories include: Referral, Office Visit, Medication (Med) Change, Hospitalization, Emergency Room (ER) Visit, Device Reprogrammed, System Modification, Increase Monitoring, Other</description>
          <units>Total number actions/total number CAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Referral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005"/>
                    <measurement group_id="O2" value="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016"/>
                    <measurement group_id="O2" value="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Med Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053"/>
                    <measurement group_id="O2" value="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device Reprogrammed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016"/>
                    <measurement group_id="O2" value="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>System Modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase Monitoring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011"/>
                    <measurement group_id="O2" value="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047"/>
                    <measurement group_id="O2" value="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of New Onset Atrial Tachycardia/Atrial Fibrillation (AT/AF) at 12 Months</title>
        <description>Compare time to first diagnosis in Remote and Control arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <population>Only participants without a history of Atrial Tachycardia/Atrial Fibrillation were included in analysis of this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of New Onset Atrial Tachycardia/Atrial Fibrillation (AT/AF) at 12 Months</title>
          <description>Compare time to first diagnosis in Remote and Control arms</description>
          <population>Only participants without a history of Atrial Tachycardia/Atrial Fibrillation were included in analysis of this objective.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Sensed Ventricular Rate Greater Than 100 Beats Per Minute (BPM) During Atrial Tachycardia/Atrial Fibrillation at 12 Months</title>
        <description>Compare time to diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Sensed Ventricular Rate Greater Than 100 Beats Per Minute (BPM) During Atrial Tachycardia/Atrial Fibrillation at 12 Months</title>
          <description>Compare time to diagnosis in Control and Remote arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Atrial Tachycardia/Atrial Fibrillation Greater Than 48 Hours at 12 Months</title>
        <description>Compare time to diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <population>Cohort was subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed vs other endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Atrial Tachycardia/Atrial Fibrillation Greater Than 48 Hours at 12 Months</title>
          <description>Compare time to diagnosis in Control and Remote arms</description>
          <population>Cohort was subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed vs other endpoint analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Ventricular Pacing Increase Greater Than 30 Percent at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Ventricular Pacing Increase Greater Than 30 Percent at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Non-sustained Ventricular Tachycardia at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Non-sustained Ventricular Tachycardia at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Loss of Atrial Capture at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <population>Analysis used subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Loss of Atrial Capture at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <population>Analysis used subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Loss of Ventricular Capture at 12 Months</title>
        <description>Compare time to first diagnosis in Remote and Control arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Loss of Ventricular Capture at 12 Months</title>
          <description>Compare time to first diagnosis in Remote and Control arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase in Atrial Pacing Voltage Threshold Greater Than 1 Volt (V) at 12 Months</title>
        <description>Compare time to first diagnosis in Remote and Control arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <population>Cohort was subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase in Atrial Pacing Voltage Threshold Greater Than 1 Volt (V) at 12 Months</title>
          <description>Compare time to first diagnosis in Remote and Control arms</description>
          <population>Cohort was subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Increase in Ventricular Pacing Voltage Threshold Greater Than 1 Volt (V) at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Increase in Ventricular Pacing Voltage Threshold Greater Than 1 Volt (V) at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Change in Atrial Lead Impedance at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <population>Cohort was subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Change in Atrial Lead Impedance at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <population>Cohort was subset of full cohort excluding participants with single chamber devices, thus the variance in number analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Change in Ventricular Lead Impedance at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Change in Ventricular Lead Impedance at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Diagnosis of Elective Replacement Indicator/Battery End of Life (ERI/EOL) at 12 Months</title>
        <description>Compare time to first diagnosis in Control and Remote arms</description>
        <time_frame>One year post-enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care With TTM</title>
            <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
          </group>
          <group group_id="O2">
            <title>Remote Pacemaker Interrogation</title>
            <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Diagnosis of Elective Replacement Indicator/Battery End of Life (ERI/EOL) at 12 Months</title>
          <description>Compare time to first diagnosis in Control and Remote arms</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were not collected for this protocol.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care With TTM</title>
          <description>Pacemaker patients followed by transtelephonic monitoring at 2 month intervals</description>
        </group>
        <group group_id="E2">
          <title>Remote Pacemaker Interrogation</title>
          <description>Pacemaker patients followed by remote pacemaker interrogation at 3 month intervals</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In most cases, contracts allow investigators (&quot;PI&quot;) to publish per the publication strategy/Clinical Investigation Plan following Medtronic's review for (a) disclosure of confidential information (&quot;CI&quot;), and (b) selection and order of publications by the publications committee. Any such CI is deleted prior to publication/presentation. Medtronic may not otherwise censor/interfere with the publication. PIs may not publish single-site data until the main multi-site publication has occurred.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CRDM Clinical</name_or_title>
      <organization>Medtronic CRDM</organization>
      <phone>800-328-2518</phone>
      <email>medtroniccrmtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

